Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07828054 | Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan(MARGARET) | not yet recruiting | Phase 3 | 244 | Mario Negri Institute for Pharmacological ResearchOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) | not yet recruiting | Phase 3 | 436 | Sichuan Baili Pharmaceutical Co., Ltd. |
| 1 |
| Aug 26, 2026 |
| clinicaltrials |
| NCT07784036 | JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer | not yet recruiting | Phase 3 | 171 | Chengdu JOYO pharma Co., Ltd.INDUSTRY | 0 | Aug 25, 2026 | clinicaltrials |
| NCT07760844 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC(SCHBCC-N0117) | not yet recruiting | Phase 3 | 180 | Fudan UniversityOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07761325 | Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy | not yet recruiting | Phase 3 | 374 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07757958 | Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast Cancer(APROOB) | not yet recruiting | Phase 3 | 520 | Samsung Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer(ADAPT-TN-IV) | not yet recruiting | Phase 3 | 765 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748260 | De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast(neoDIRHP) | not yet recruiting | Phase 3 | 592 | Guangdong Provincial People's HospitalOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07683754 | T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd(DB-Guide) | not yet recruiting | Phase 3 | 200 | Daiichi SankyoINDUSTRY | 0 | Jul 23, 2026 | clinicaltrials |
| NCT07717450 | Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.(TAILORswitch) | not yet recruiting | Phase 3 | 370 | UNICANCEROTHER | 0 | Jul 21, 2026 | clinicaltrials |
| NCT07695948 | Effects, Metabolic Mechanisms and Predictors of Response to Acupuncture in Treating Psychoneurological Symptoms Among Breast Cancer Survivors | not yet recruiting | Phase 3 | 252 | University of Illinois at ChicagoOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07684456 | Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer | not yet recruiting | Phase 3 | 308 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC(TRIBE) | not yet recruiting | Phase 3 | 140 | Fudan UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | not yet recruiting | Phase 3 | 562 | SWOG Cancer Research NetworkNETWORK | 0 | May 27, 2026 | clinicaltrials |
| NCT07593846 | The Comparison Between DEDTI BR and T/E BR(DETE-BR) | not yet recruiting | Phase 3 | 412 | West China HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07554573 | Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)(ABCD RT) | not yet recruiting | Phase 3 | 5,270 | NRG OncologyOTHER | 0 | Apr 28, 2026 | clinicaltrials |
| NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy(PLANET) | not yet recruiting | Phase 3 | 1,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT07483996 | Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer(CRYSTAL) | not yet recruiting | Phase 3 | 938 | Franciscus Gasthuis & Vlietland (Hospital)OTHER | 0 | Mar 19, 2026 | clinicaltrials |
| NCT07410169 | Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy | not yet recruiting | Phase 2 / Phase 3 | 160 | Guangdong Provincial People's HospitalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07407517 | Adjuvant Intensification for LAR(POLARIS) | not yet recruiting | Phase 3 | 904 | Fudan UniversityOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07385365 | A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer | not yet recruiting | Phase 3 | 3,142 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07382687 | Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype | not yet recruiting | Phase 3 | 248 | Fudan UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07372144 | Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment(IARA) | not yet recruiting | Phase 3 | 227 | D'Or Institute for Research and EducationOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07366840 | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure(BRIGHT) | not yet recruiting | Phase 2 / Phase 3 | 268 | Fudan UniversityOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07269691 | RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer | not yet recruiting | Phase 3 | 194 | Pengfei QiuOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06787118 | Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer(PANDORA) | not yet recruiting | Phase 3 | 130 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07213206 | CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer(Cinderella) | not yet recruiting | Phase 3 | 1,500 | Fudan UniversityOTHER | 0 | Oct 8, 2025 | clinicaltrials |
| NCT06835400 | Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer | not yet recruiting | Phase 3 | 340 | Health Hope PharmaINDUSTRY | 0 | Jul 11, 2025 | clinicaltrials |
| NCT06434077 | Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer | not yet recruiting | Phase 3 | 60 | S.LAB (SOLOWAYS)OTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07021261 | Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | not yet recruiting | Phase 3 | 440 | Fudan UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07005557 | Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer(SENIOR) | not yet recruiting | Phase 3 | 1,244 | Fudan UniversityOTHER | 0 | Jun 5, 2025 | clinicaltrials |
| NCT06996093 | Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor | not yet recruiting | Phase 3 | 2,508 | Fudan UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06223698 | Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer(SWE-Switch) | not yet recruiting | Phase 3 | 3,832 | Region Örebro CountyOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06811220 | The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients | not yet recruiting | Phase 3 | 140 | Alexandria UniversityOTHER | 0 | Feb 6, 2025 | clinicaltrials |
| NCT06795503 | Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients | not yet recruiting | Phase 3 | 1,462 | Fudan UniversityOTHER | 0 | Jan 28, 2025 | clinicaltrials |
| NCT06769919 | A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer | not yet recruiting | Phase 2 / Phase 3 | 340 | Xijing HospitalOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06407401 | Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer | not yet recruiting | Phase 3 | 399 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06270355 | Stockholm Mammography Risk Stratified Trial(SMART) | not yet recruiting | Phase 3 | 70,000 | Karolinska InstitutetOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06268327 | Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 30 | Assiut UniversityOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT05993559 | Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy | not yet recruiting | Phase 3 | 1,314 | Gangnam Severance HospitalOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT05841381 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | not yet recruiting | Phase 3 | 876 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05253170 | Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients | not yet recruiting | Phase 3 | 622 | Seoul National University Bundang HospitalOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT04973319 | Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | not yet recruiting | Phase 3 | 450 | Shengjing HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04736589 | Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | not yet recruiting | Phase 3 | 270 | Peking Union Medical CollegeOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 3 | 522 | Shanghai Henlius BiotechINDUSTRY | 0 | Mar 12, 2020 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials